366 related articles for article (PubMed ID: 33149148)
1. Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.
Desbois M; Udyavar AR; Ryner L; Kozlowski C; Guan Y; Dürrbaum M; Lu S; Fortin JP; Koeppen H; Ziai J; Chang CW; Keerthivasan S; Plante M; Bourgon R; Bais C; Hegde P; Daemen A; Turley S; Wang Y
Nat Commun; 2020 Nov; 11(1):5583. PubMed ID: 33149148
[TBL] [Abstract][Full Text] [Related]
2. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Cao Y; Trillo-Tinoco J; Sierra RA; Anadon C; Dai W; Mohamed E; Cen L; Costich TL; Magliocco A; Marchion D; Klar R; Michel S; Jaschinski F; Reich RR; Mehrotra S; Cubillos-Ruiz JR; Munn DH; Conejo-Garcia JR; Rodriguez PC
Nat Commun; 2019 Mar; 10(1):1280. PubMed ID: 30894532
[TBL] [Abstract][Full Text] [Related]
3. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783
[TBL] [Abstract][Full Text] [Related]
4. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors.
Cremasco V; Astarita JL; Grauel AL; Keerthivasan S; MacIsaac K; Woodruff MC; Wu M; Spel L; Santoro S; Amoozgar Z; Laszewski T; Migoni SC; Knoblich K; Fletcher AL; LaFleur M; Wucherpfennig KW; Pure E; Dranoff G; Carroll MC; Turley SJ
Cancer Immunol Res; 2018 Dec; 6(12):1472-1485. PubMed ID: 30266714
[TBL] [Abstract][Full Text] [Related]
5. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells.
Lai D; Ma L; Wang F
Int J Oncol; 2012 Aug; 41(2):541-50. PubMed ID: 22614695
[TBL] [Abstract][Full Text] [Related]
8. Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors.
Zhang Y; Ertl HC
Oncotarget; 2016 Apr; 7(17):23282-99. PubMed ID: 26943036
[TBL] [Abstract][Full Text] [Related]
9. Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer.
Yang M; Zhang G; Wang Y; He M; Xu Q; Lu J; Liu H; Xu C
Br J Cancer; 2020 Oct; 123(9):1404-1416. PubMed ID: 32778818
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of the immune microenvironment in ovarian cancer patients.
Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
[TBL] [Abstract][Full Text] [Related]
11. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
12. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
13. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
[TBL] [Abstract][Full Text] [Related]
14. Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, TGFbeta3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer.
Nilsson E; Doraiswamy V; Parrott JA; Skinner MK
Mol Cell Endocrinol; 2001 Sep; 182(2):145-55. PubMed ID: 11514049
[TBL] [Abstract][Full Text] [Related]
15. Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis.
Chang CC; Su KM; Lu KH; Lin CK; Wang PH; Li HY; Wang ML; Lin CK; Yu MH; Chang CM
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30356023
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer.
Liu J; Chen C; Wang Y; Qian C; Wei J; Xing Y; Bai J
Front Immunol; 2021; 12():746647. PubMed ID: 34777359
[TBL] [Abstract][Full Text] [Related]
18. Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells.
Zhou J; Jain S; Azad AK; Xu X; Yu HC; Xu Z; Godbout R; Fu Y
Cell Signal; 2016 Aug; 28(8):838-49. PubMed ID: 27075926
[TBL] [Abstract][Full Text] [Related]
19. Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.
Sekiya A; Suzuki S; Tanaka A; Hattori S; Shimizu Y; Yoshikawa N; Koya Y; Kajiyama H; Kikkawa F
Int J Oncol; 2019 Sep; 55(3):755-765. PubMed ID: 31322193
[TBL] [Abstract][Full Text] [Related]
20. ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.
Cheon DJ; Li AJ; Beach JA; Walts AE; Tran H; Lester J; Karlan BY; Orsulic S
Carcinogenesis; 2015 Jul; 36(7):739-47. PubMed ID: 25926422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
